Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Sands Cancer Center — Canandaigua, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Northwell Health Physicians Partners Radiation Medicine at Queens — Forest Hills, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Guthrie Cortland Memorial Hospital — Cortland, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in New York: - MSK Commack — Commack, New York
- MSKCC-Westchester (500 Westchester Ave.) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (IDS Pharmacy) — Long Island City, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC). — New York, New York
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in New York: - Associated Medical Professionals - Urology ( Site 0081) — Syracuse, New York
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in New York: - James J. Peters VA Medical Center ( Site 0088) — The Bronx, New York
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in New York: - Adaptive Research Inc. — Hawthorne, New York
- Queens Hospital Center — Jamaica, New York
- Columbia University Medical Center — New York, New York
- James J. Peters VA Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in New York: - Montefiore Medical Center - Medical Park — The Bronx, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in New York: - Memorial Sloan Kettering Cancer Ctr — New York, New York
- Associated Med Professionals of NY — Syracuse, New York
- Montefiore Hospital — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in New York: - Associated Med Professionals of NY — Syracuse, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in New York: - Mount Sinai Doctors Urology Faculty Practice — New York, New York
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in New York: - Research Site — New Hyde Park, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in New York: - Weill Cornell — New York, New York
Phase 3 Recruiting Academic/Other
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07548164
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) — Harrison, New York
- Weill Cornell Medical Center (Data Collection Only) — New York, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researcher…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06986083
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Consent only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York
Phase 2, Phase 3 Recruiting Academic/Other
To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery afte…
Sponsor: John Elfar
NCT ID: NCT03701581
Sites in New York: - University of Rochester — Rochester, New York
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in New York: - Garnet Health Medical Center — Middletown, New York
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Mount Sinai Hospital — New York, New York
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in New York: - Site US10024 — Garden City, New York
- Site US10055 — New York, New York
- Site US10059 — New York, New York
- Hudson Valley Urology, PC — Poughkeepsie, New York
- Site US10053 — Syracuse, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in New York: - Integrated Medical Professionals — North Hills, New York
- Associated Medical Professionals of NY — Syracuse, New York
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in New York: - Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY — New York, New York
- James J. Peters VA Medical Center, Bronx, NY — The Bronx, New York